Bicycle Therapeutics: Westfield reports 0 shares

Bicycle Therapeutics plc received an amended Schedule 13G/A filing from Westfield Capital Management Company, L.P. reporting 0 shares beneficially owned of common stock, representing 0% as of 12/31/2025.

Accepted by SEC EDGAR 03/03/2026 - 05:27 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Bicycle Therapeutics plc received an amended Schedule 13G/A filing from Westfield Capital Management Company, L.P. reporting 0 shares beneficially owned of common stock, representing 0% as of 12/31/2025. The amendment is signed by Brandi McMahon, Vice President, Deputy Chief Compliance Officer, dated 03/03/2026.

Insights

Compliance Analyst

Amendment confirms no beneficial ownership as of the reporting date.

The filing is an amended Schedule 13G/A from Westfield Capital Management Company, L.P. stating 0 shares and 0% ownership as of 12/31/2025. This is a routine ownership disclosure update rather than a transaction.

Timing and signature are shown: signed by Brandi McMahon on 03/03/2026. Subsequent filings would show any change in holdings.

Corporate Governance Specialist

Disclosure indicates no reportable stake, limiting immediate governance influence.

The schedule explicitly lists zero votes and zero dispositive power for Westfield across all categories, consistent with ownership of 5 percent or less disclosures. This filing does not alter board composition or shareholder voting dynamics.

Investors seeking changes in ownership should watch future amendments or Section 13 filings for updated share counts and percentages.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Westfield Capital report in the BCYC Schedule 13G/A?

The filing reports 0 shares beneficially owned of Bicycle Therapeutics common stock, representing 0% of the class as of 12/31/2025. It is an amended disclosure signed on 03/03/2026.

Does the Schedule 13G/A indicate any voting or dispositive power for Westfield Capital?

No. The schedule lists 0 for sole and shared voting power and for sole and shared dispositive power. The filer reports no authority to vote or dispose of BCYC shares as of 12/31/2025.

Who signed the amended Schedule 13G/A for BCYC and when?

The amendment is signed by Brandi McMahon, Vice President, Deputy Chief Compliance Officer, with a signature date of 03/03/2026. The reporting person is Westfield Capital Management Company, L.P.

Is this Schedule 13G/A a transaction filing for BCYC?

No. This is an ownership disclosure amendment reporting a passive position of 0 shares. It does not report a purchase or sale transaction; it updates beneficial ownership information as of 12/31/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

BICYCLE THERAPEUTICS PLC

(Name of Issuer)

Common Stock

(Title of Class of Securities)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP Number(s):

1

Names of Reporting Persons

Westfield Capital Management Company, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MASSACHUSETTS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: BICYCLE THERAPEUTICS PLC
(b)	Address of issuer's principal executive offices: BLOCKS A & B, PORTWAY BUILDING, GRANTA PARK, GREAT ABINGTON, CAMBRIDGE, UNITED KINGDOM CB21 6GS
Item 2.
(a)	Name of person filing: Westfield Capital Management Company, L.P.
(b)	Address or principal business office or, if none, residence: 1 Financial Center, 24th Floor Boston, Massachusetts 02111
(c)	Citizenship: Westfield Capital Management Company, L.P. - MASSACHUSETTS
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 088786108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 0
(b)	Percent of class: 0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Westfield Capital Management Company, L.P. - 0
	(ii) Shared power to vote or to direct the vote: Westfield Capital Management Company, L.P. - 0
	(iii) Sole power to dispose or to direct the disposition of: Westfield Capital Management Company, L.P. - 0
	(iv) Shared power to dispose or to direct the disposition of: Westfield Capital Management Company, L.P. - 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Westfield Capital Management Company, L.P.

Signature:	Brandi McMahon
Name/Title:	Vice President, Deputy Chief Compliance Officer
Date:	03/03/2026